Phase III
Novartis, a leader reimagining rheumatology and immunodermatology, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with nr-axSpA (non-radiographic axial spondyloarthritis).
The trial is still ongoing, but met its primary endpoint of ASAS40.
BioCardia announced that the independent Data Safety Monitoring Board has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which included safety follow-up results on 35 patients and all additional data available on the 50 patients randomized in the trial as of August 31, 2019.
Celgene announced topline data from its Phase III QUAZAR AML-001 trial.
OV101 May Become the First Medicine for Individuals with Angelman Syndrome; Topline Results Expected in Mid-2020
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
The Data Safety Monitoring Board ran a safety review and recommended the trials end because of an unfavorable risk-benefit ratio.
Tocagen said the late-stage Toca 5 trial evaluating Toca 511 & Toca FC in patients with recurrent high-grade glioma undergoing resection missed its overall survival endpoint compared to standard of care treatment.
Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures
The results of the two long-term trials showed that patients receiving the company’s checkpoint inhibitor, Opdivo (nivolumab), had a long-term overall survival improvement compared to docetaxel chemotherapy alone.
PRESS RELEASES